The Breakthrough
Google DeepMind unveiled AlphaFold 4, the latest iteration of its revolutionary protein structure prediction system. While AlphaFold 2 and 3 predicted static protein structures, AlphaFold 4 models the dynamic conformational changes proteins undergo when binding to drug molecules — a critical factor in drug efficacy.
Key Capabilities
- Predicts protein-drug binding dynamics with 92% accuracy (up from 61% in AlphaFold 3)
- Models allosteric effects — how drug binding at one site affects the whole protein
- Simulates binding affinity across thousands of drug candidates in minutes
- Integrates with lab automation for closed-loop drug discovery
Pharma Partnerships
Eli Lilly, Novartis, and AstraZeneca have signed early access agreements. Eli Lilly reported that AlphaFold 4 identified three promising Alzheimer's drug candidates that traditional screening missed entirely. Novartis is using it to repurpose existing drugs for rare diseases.
Open Access
DeepMind will release the model weights for academic use, continuing its commitment to open science. A commercial API through Isomorphic Labs will serve pharmaceutical companies with enterprise support and compliance features.